Fate Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview

Fate Therapeutics

28/07/2023 13:35

* Fate Therapeutics Inc  FATE.OQ   FATE.O  is expected
to show a
fall in quarterly revenue when it reports  results on August 1
(estimated). 
    * The San Diego California-based  company is expected to
report  a
70.2% decrease in revenue to $5.528 million from $18.55 million
a year ago, according to the mean estimate from 18 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Fate Therapeutics
Inc is
for a loss of 59 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 14
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fate
Therapeutics
Inc is $7​, above​ its last closing price of $4.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.64       -0.62      -0.19     Beat    69.5
 Dec. 31 2023  -0.85       -0.86      -0.58     Beat    32.7
 Sep. 30 2022  -0.87       -0.89      -0.86     Beat    3.7​
 Jun. 30 2022  -0.81       -0.83      -0.79     Beat    4.4
 ​​Mar.        -0.77       -0.77      -0.68     Beat    11.1
 31 2022                                                
 Dec. 31 2021  -0.65       -0.67      -0.72     Missed  -8​
 Sep. 30 2021  -0.59       -0.58      -0.45     Beat    22.6
 Jun. 30 2021  -0.54       -0.53      -0.58     Missed  -10
 This summary was machine generated July 28 at 12:35 GMT.  All
figures in US dollars  unless otherwise stated